Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer

  • STATUS
    Recruiting
  • participants needed
    20
Updated on 19 February 2024

Summary

This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care or another study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. Patients who come to the University of Pennsylvania for diagnosis and/or treatment of pancreatic cancer and who meet the study inclusion criteria may be approached by study personnel for recruitment into this study. Patients will be approached about study participation regardless of race or ethnic background. We anticipate enrolling up to 30 participants. Accrual will likely occur over approximately 2-3 years. After undergoing screening assessments and verifying eligibility for study participation subjects will undergo an experimental [18F]FTT PET/CT scan. If a patient is going to biopsy then tumor tissue may be obtained for research purposes if there is enough tissue available for research. Patients may return for an optional second FTT PET/CT scan approximately 3 weeks after the start of PARP inhibitor therapy.

Details
Condition pancreatic cancer
Age 99years or below
Clinical Study Identifier03492164
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.